These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

722 related articles for article (PubMed ID: 29761297)

  • 1. Severe neurologic complications of immune checkpoint inhibitors: a single-center review.
    Mancone S; Lycan T; Ahmed T; Topaloglu U; Dothard A; Petty WJ; Strowd RE
    J Neurol; 2018 Jul; 265(7):1636-1642. PubMed ID: 29761297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
    Le Burel S; Champiat S; Mateus C; Marabelle A; Michot JM; Robert C; Belkhir R; Soria JC; Laghouati S; Voisin AL; Fain O; Mékinian A; Coutte L; Szwebel TA; Dunogeant L; Lioger B; Luxembourger C; Mariette X; Lambotte O
    Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurological toxicities associated with immune-checkpoint inhibitors.
    Touat M; Talmasov D; Ricard D; Psimaras D
    Curr Opin Neurol; 2017 Dec; 30(6):659-668. PubMed ID: 28938341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
    Reynolds KL; Guidon AC
    Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition.
    Pan PC; Haggiagi A
    Curr Oncol Rep; 2019 Nov; 21(12):108. PubMed ID: 31776691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances on immune-related adverse events associated with immune checkpoint inhibitors.
    Fan Y; Geng Y; Shen L; Zhang Z
    Front Med; 2021 Feb; 15(1):33-42. PubMed ID: 32779094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
    Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
    Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
    Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
    Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
    Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Course of Neurologic Adverse Events Associated With Immune Checkpoint Inhibitors: Focus on Chronic Toxicities.
    Rossi S; Farina A; Malvaso A; Dinoto A; Fionda L; Cornacchini S; Florean I; Zuliani L; Garibaldi M; Lauletta A; Baccari F; Zenesini C; Rinaldi R; Mariotto S; Damato V; Diamanti L; Gastaldi M; Vogrig A; Marchioni E; Guarino M
    Neurol Neuroimmunol Neuroinflamm; 2024 Nov; 11(6):e200314. PubMed ID: 39298719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation.
    Yang H; Yao Z; Zhou X; Zhang W; Zhang X; Zhang F
    Clin Immunol; 2020 Apr; 213():108377. PubMed ID: 32135278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoimmune complications of immunotherapy: pathophysiology and management.
    Chan KK; Bass AR
    BMJ; 2020 Apr; 369():m736. PubMed ID: 32253223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea.
    Hyun JW; Kim KH; Kim SH; Kim HJ
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5583-5589. PubMed ID: 36495331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer.
    Berti A; Bortolotti R; Dipasquale M; Kinspergher S; Prokop L; Grandi G; Inchiostro S; Paolazzi G; Caffo O; Veccia A
    Crit Rev Oncol Hematol; 2021 Jun; 162():103351. PubMed ID: 33989769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors.
    Feng S; Coward J; McCaffrey E; Coucher J; Kalokerinos P; O'Byrne K
    J Thorac Oncol; 2017 Nov; 12(11):1626-1635. PubMed ID: 28843363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events.
    Teimouri A; Minard LV; Scott SN; Daniels A; Snow S
    Curr Oncol; 2022 Apr; 29(5):3104-3117. PubMed ID: 35621642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed immune-related adverse events in long-responders of immunotherapy: a single-center experience.
    Kitano M; Honda T; Hikita E; Masuo M; Miyazaki Y; Kobayashi M
    Asia Pac J Clin Oncol; 2024 Aug; 20(4):463-471. PubMed ID: 38608154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.